Thursday, April 16, 2009

HIV deal shows need for new pharmaceutical models

The pharmaceutical industry is going back to the lab for its business models as it faces historic challenges.
Large drugmakers are experimenting with various collaborations as their major products face revenue declines, research productivity stalls, and governments and health insurers crack down on drug prices and healthcare costs.
The new ventures -- from deals on products to mega mergers -- seek to meet these challenges by cutting costs and mitigating the risks of research into new treatments.
Post a Comment